Introduction
============

Single-nucleotide polymorphisms (SNPs) in drug metabolizing enzymes have an considerable effect on drug absorption, metabolism, distribution, and excretion and can lead to completely different efficacies and/or adverse reactions (ADRs).[@b1-cmar-10-6217],[@b2-cmar-10-6217] Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), which converts 7-ethyl-10-hydroxy camptothecin (SN-38) to SN-38 glucuronide (SN-38G), is a critical enzyme for irinotecan (CPT-11), which is the first-line drug for treating metastatic colorectal cancer (mCRC). Previous studies demonstrated that the incidence of life-threatening ADRs is often linked to mutant homozygotes in UGT1A1^\*^6 and ^\*^28, which reduce or inhibit UGT1A1 activity and increase plasma SN-38 concentrations;[@b3-cmar-10-6217],[@b4-cmar-10-6217] however, the incidence of the homozygous genotype is \<10% in Asian population.[@b5-cmar-10-6217],[@b6-cmar-10-6217] Thus, in addition to screening for homozygous genotypes that may cause serious ADRs, the main purpose of CPT-11 individualized therapy for these patients is to elucidate whether the pharmacokinetics of CPT-11 is correlated with clinical outcomes so that the dose can be adjusted within a relatively short period to achieve better results.

There may be a widely variable range of UGT1A1 activity for UGT1A1^\*^6 and/or ^\*^28 heterozygous types (including ^\*^1/^\*^28-^\*^1/^\*^1, ^\*^1/^\*^1-^\*^1/^\*^6, and ^\*^1/^\*^28-^\*^1/^\*^6 genotypes). Theoretically, to achieve personalized administration, the best strategy is to relate CPT-11 pharmacokinetics parameters with the UGT1A1^\*^6 and ^\*^28 genotypes, rather than relying on one factor.[@b7-cmar-10-6217] However, the relationship between plasma SN-38 levels or concentration--time curve (area under the curve \[AUC\]) and clinical efficacy remains unclear, which may be related to the different distribution of UGT1A1^\*^28 and UGT1A1^\*^6 genotypes between population and poor clinical operations of calculating SN-38/SN-38G AUC for the following CPT-11 dosage. Thus, the maximum tolerance dose (MTD) is determined only by dose escalation.[@b8-cmar-10-6217],[@b9-cmar-10-6217] Our previous studies showed that plasma SN-38 level 1.5 hours after CPT-11 administration (C~SN-38\ 1.5h~) was related to progression-free survival (PFS) for UGT1A1^\*^6 and ^\*^28 wild-types and to better clinical efficacy for relatively high C~SN-38\ 1.5h~.[@b10-cmar-10-6217],[@b11-cmar-10-6217]

In addition, CPT-11 is routinely combined with 5-fluorouracil (5-FU) as a first-line treatment for mCRC, and 80%--85% of 5-FU is metabolized to inactive dihydro fluorouracil (DHFU) by dihydropyrimidine dehydrogenase (DPD) in the liver. Serious ADRs such as neutropenia, diarrhea, and oral mucositis, which are similar to those caused by CPT-11, occur in cases of partial or total deficiency of DPD activity, leading to inhibition of plasma 5-FU clearance;[@b12-cmar-10-6217] accordingly, the identification of CPT-11-associated ADRs may be affected. Therefore, it is important to detect DPD activities before FOLFIRI chemotherapy, which can reduce the probability of 5-FU-related ADRs by decreasing the 5-FU dosage for those with lower DPD activities to improve the effectiveness of CPT-11 individualized medication.

Assessing the SNPs UGT1A1^\*^6 and ^\*^28 and DPD activities simultaneously is a feasible strategy for dosage personalization of CPT-11, although few studies have examined this approach.[@b13-cmar-10-6217] Thus, we retrospectively explored the correlation between clinical parameters such as C~SN-38\ 1.5h~, plasma SN-38 level 49 hours after CPT-11 administration (C~SN-38\ 49h~), DPD activity, and outcomes (efficacy and ADRs) to provide a basis for individualized CPT-11 administration according to plasma SN-38 levels and DPD activity for patients with the UGT1A1^\*^28 or ^\*^6 heterozygous genotypes.

Methods
=======

Patient's eligibility
---------------------

The SNPs of UGT1A1^\*^6 and ^\*^28 were detected in 550 cases before the first chemotherapy treatment from December 2012 to May 2014, and 499 cases met the following inclusion criteria: previously untreated local advanced or mCRC with measurable lesions verified by pathological and imaging data, East Cooperative Oncology Group (ECOG) physical status score of 0--2 points, life expectancy greater than 3 months, no chemotherapy contraindication, written informed consents, serum bilirubin levels, and transaminase levels limited to 1.5-and 5-fold the normal levels, and ability to undergo administration of at least three cycles of FOLFIRI chemotherapy, as well as one assessment. Patients with complete or incomplete intestinal obstruction, chronic enteritis, a history of extensive colectomy, severe allergy to CPT-11 or 5-FU, other malignant tumors and central nervous system metastases, previously treated measurable lesions such as by radiotherapy or local interventional therapy, major organ dysfunction, and poor compliance and pregnancy were ruled out. A total of 234 cases confirmed with UGT1A1^\*^28 and/or ^\*^6 heterozygous genotype were analyzed, which include those from the Zhongshan Hospital (54 cases), Cancer Medical Center (43 cases) affiliated with Fudan University Shanghai Medical College, Ruijin Hospital (41 cases), Renji Hospital (36 cases), and General Hospital (30 cases) affiliated with Shanghai Jiaotong University Medical of School and Shanghai Tenth People's Hospital (20 cases) affiliated with Tongji University ([Table 1](#t1-cmar-10-6217){ref-type="table"}).

SNPs analysis for UGT1A1
------------------------

Plasma genomic DNA was collected using a DNA purification kit (Qiagen, Hilden, Germany), and gene fragments containing UGT1A1^\*^6 and ^\*^28 polymorphism sites were amplified by PCR (25 µL): 2 µL of 10× PCR buffer (15 mM MgCl~2~), 2 µL of dNTP (2.5 mM), 0.5 µL of sense and antisense primers (10 µM), 0.2 µL of Taq DNA polymerase (5 U/µL), 1 µL of DNA templates, and 18.8 µL of double-distilled water (ddH~2~O). The primer pairs for ^\*^6 and ^\*^28 polymorphism points in the *UGT1A1* gene were designed as follows: upstream, 5′-TCCCTGCTACCTTTGTG-GAC-3′; downstream, 5′-AGCAGGCCCAGGACAAGT-3′. The conditions of PCR amplification were as follows: initial denaturation at 94°C for 5 minutes, followed by 40 cycles of denaturation at 94°C for 15 seconds, annealing at 55°C for 25 seconds, extension at 72°C for 50 seconds, and then extension at 72°C for 7 minutes. Next, 5 µL of eligible PCR samples showing clear and stable bands in gel electrophoresis were mixed with 2 µL of shrimp ALP (SAP) and then stored at 4°C after incubation at 37°C for 60 minutes and subsequent incubation at 80°C for 15 minutes. Approximately 3 µL of positive PCR enzymatic hydrolysates, 1 µL of sequencing reagent (BigDye^®^ ; Applied Biosystems, Foster City, CA, USA), and 2 µL of sequencing primer containing fragments of UGT1A1^\*^28 and UGT1A1^\*^6 were used for PCR amplification. The primer pairs were designed and synthesized as follows: UGT1A1^\*^28 primer: forward; 5′-CAGCCTCAAGACCCCACA-3′, reverse: 5′-TGCTCCTGCCAGAGGTTC-3′; UGT1A1^\*^6 primer: forward: 5′-TCCCTGCTACCTTTGTGGA-3′, reverse: 5′-AGGAAAGGGTCCGTCAGC-3′. PCR amplification was conducted in 25 cycles of denaturation at 96°C for 10 seconds, annealing at 50°C for 5 seconds, and extension at 60°C after an initial denaturation at 96°C for 1 minute; the temperature was maintained at 4°C after the reaction. Finally, the reaction products were directly sequenced with a DNA sequencer (ABI-373; Thermo Fisher Scientific, Waltham, MA, USA), and the sequencing results were analyzed and displayed by FinchTV^®^ software.

DPD activity (UH~2~/U) determination
------------------------------------

The internal standard, composed of 250 µL of plasma and 50 µL of 5-bromouracil (5-BrU) solution (2 µg/mL), was added to 1.5 mL extraction solution consisting of *n*-propanol: *tert*-butyl ether (25:75, *v*/*v*), and the mixture was vortexed for 2 minutes and centrifuged at 3,550× *g* for 5 minutes. The abovementioned steps were repeated after the organic phase was separated. The inorganic phase was dried with nitrogen and redissolved in 18 µL of ddH~2~O, and then 20 µL of dichlo-romethane was added after vortex mixing for 30 seconds, followed by centrifugation at 2,250× *g* for 10 minutes. After vortexing for 5 seconds, 10 µL of the supernatant was injected into a high-performance liquid chromatography system. UH~2~/U detection was performed using the Shimadzu UFLC chromatographic system (Shimadzu Corporation, Kyoto, Japan), which was equipped with two LC-20AD pumps, a model DGU-20A3 degasser unit, an SIL-20A autosampler, a CTO-20AC thermosetted column compartment, and a model RF-10AXL fluorescence detector. Data were processed with Shimadzu LC-Solution chromatography software (version 1.21, SP1). Analytes were separated at room temperature using a Welch Ultimate XB-C18 column (4.6×150 mm, 5 µm). Detection was carried out with 20 µL of injection volume at an excitation wavelength of 385 nm and emission wavelength of 535 nm at a column temperature of 25°C. The mobile phase consisted of acetonitrile:0.05 M Na~2~HPO~4~ salt solution:triethylamine (72.5:27.5:0.5, v:v:v) with a flow rate at 1.0 mL/min and was adjusted to pH 5.0 by phosphate.

Detection of plasma SN-38 levels
--------------------------------

SN-38 and internal standard were dissolved in 50% methanol at a concentration of 1.0 mg/mL and stored at −80°C. To draw a calibration curve, an appropriate volume of standard working solution was added to 180 µL aliquots of blank human plasma ranging from 5 to 1,500 ng/mL. All samples were mixed with 100 µL of 7% perchloric acid, vortexed for 3 minutes, and centrifuged at 15,800× *g* for 10 minutes. Plasma SN-38 levels were detected using the Shimadzu UFLC chromatographic system as described earlier. Data were processed with Shimadzu LC-Solution chromatography software (version 1.21, SP1).

Evaluation and follow-up
------------------------

The first evaluation was conducted after three cycles of chemotherapy according to evaluation criteria for the curative effect of solid tumor (Response Evaluation Criteria in Solid Tumors, edition 1.1) for all patients. Efficacy reconfirmation was evaluated 4 weeks later for those who achieved complete or partial remission. ADRs were graded under the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0). Patients could be administered other treatments such as second-line chemotherapy with or without molecular targeted drugs and best support care after progression and were visited every 3 months for survival analysis. The median follow-up time was 15 months (range, 8--22 months).

Statistical methods
-------------------

The measurement data were presented as the mean±SD, and the enumeration data were expressed as a rate or composition using SPSS^®^ statistic software (version 19.0; IBM Corporation, Armonk, NY, USA). The Student's *t*-test was used for the measurement data such as plasma drug level comparison. Chi-squared test and one-way ANOVA were used for intergroup analysis of classification or connectivity evaluation index such as differences of ADRs. Kaplan--Meier test and Log-rank test were used to determine the differences in survival and efficacy between groups. A *P*-value \<0.05 was considered to indicate significant results.

Results
=======

SNPs and proportion for UGT1A1^\*^6 and/or ^\*^28 heterozygous genotype
-----------------------------------------------------------------------

The sequencing results are shown in [Figure 1A--F](#f1-cmar-10-6217){ref-type="fig"} for the 234 cases with the UGT1A1^\*^6 and/or ^\*^28 heterozygous genotype (accounting for 46.89%), including 116 cases of the ^\*^1/^\*^1-^\*^1/^\*^6 genotype, 98 cases of the ^\*^1/^\*^28-^\*^1/^\*^1 genotype, and 20 cases of the ^\*^1/^\*^28-^\*^1/^\*^6 genotype. The constituent ratio is shown in [Figure 1G](#f1-cmar-10-6217){ref-type="fig"}.

C~SN-38\ 1.5h~ and C~SN-38\ 49h~ between UGT1A1^\*^6 and ^\*^28 wild-type and UGT1A1^\*^6 and/or ^\*^28 heterozygous genotype
-----------------------------------------------------------------------------------------------------------------------------

As shown in [Figure 2A](#f2-cmar-10-6217){ref-type="fig"}, the C~SN-38\ 1.5h~ values of the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes were 61.74±11.49 and 63.10±10.29 ng/mL, respectively, which were not significantly different from that of the ^\*^1/^\*^1-^\*^1/^\*^1 genotype (60.84±11.13 ng/mL, *P*=0.57 and 0.13), but were significantly lower than that of the ^\*^1/^\*^28-^\*^1/^\*^6 genotype (75.10±23.16 ng/mL, *P*\<0.001). The same results were observed for C~SN-38\ 1.5h~ ([Figure 2B](#f2-cmar-10-6217){ref-type="fig"}).

Moreover, there were no significant differences in gender, age, ECOG performance status, location of the primary tumor, TMN staging, median of chemotherapeutic cycles, initial doses of CPT-11, and DPD activity between the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes ([Table 1](#t1-cmar-10-6217){ref-type="table"}).

Regression analysis of C~SN-38\ 1.5h~ and C~SN-38\ 49h~ with clinical parameters
--------------------------------------------------------------------------------

Stepwise regression analysis was conducted for the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes with C~SN-38\ 1.5h~ and C~SN-38\ 49h~ serving as dependent variables, and the initial doses of CPT-11, serum bilirubin levels before and after treatment, chemotherapeutic cycles, short-term response, PFS, overall survival (OS), and ADRs were independent variables. We found that C~SN-38\ 1.5h~ was related to PFS (*t*=16.81, *P*\<0.001), whereas C~SN-38\ 49h~ was related to bone marrow hypocellularity, increased alanine aminotransferase, and diarrhea in the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes (*t*=8.82, *P*\<0.001; *t*=5.02, *P*\<0.001; and *t*=4.84, *P*\<0.001, respectively; [Table 2](#t2-cmar-10-6217){ref-type="table"}).

Median PFS (mPFS) of corresponding C~SN-38\ 1.5h~ and C~SN-38\ 49h~ subgroups in ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes
-----------------------------------------------------------------------------------------------------------------------------------------------

As shown in [Figure 3](#f3-cmar-10-6217){ref-type="fig"}, the mPFS of the ^\*^1/^\*^28-^\*^1/^\*^1, ^\*^1/^\*^1-^\*^1/^\*^6, and ^\*^1/^\*^28-^\*^1/^\*^6 genotypes were 6.73±0.13, 6.73±0.18, and 6.80±0.32 months, respectively, with no significant difference between groups (χ^2^=1.11, *P*=0.57). However, a comparison of the C~SN-38\ 1.5h~\>51.82 ng/mL and C~SN-38\ 49h~\>14.34 ng/mL subsets with the ≤51.82 and≤14.34 ng/mL subsets, respectively, grouped according to the adjusted predictive values and stand errors of the plasma SN-38 levels in the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes revealed that the mPFS of the C~SN-38\ 1.5h~\>51.82 ng/mL subgroup was significantly longer than that of the ≤51.82 ng/mL subgroup (6.83±0.17 vs 4.87±0.13 months, 6.93±0.34 vs 5.63±0.31 months; *P*\<0.001, *P*\<0.001), but no significant difference was observed in mPFS between the C~SN-38\ 49h~\>14.34 ng/mL subgroup and ≤14.34 ng/mL subgroup (6.83±0.48 vs 6.63±0.13 months, 7.27±0.35 vs 6.70±0.21 months, *P*=0.80 and *P*=0.59).

ADRs between corresponding C~SN-38\ 1.5h~ and C~SN-38\ 49h~ subgroups in ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes
---------------------------------------------------------------------------------------------------------------------------------------

Given the relationship between C~SN-38\ 49h~ and bone marrow hypocellularity in the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes, the incidence of ADRs was compared between the C~SN-38\ 49h~\>14.34 and≤14.34 ng/mL subgroups; the results showed that the incidence of bone marrow hypocellularity, diarrhea, increased alanine aminotransferase, nausea, and oral mucositis in the C~SN-38\ 49h~\>14.34 ng/mL subgroup was significantly higher than that in the ≤14.34 ng/mL subgroup (*P*\<0.001, *P*\<0.001, *P*\<0.001, *P*\<0.001, and *P*\<0.001); however, the difference between the C~SN-38\ 1.5h~\>51.82 and ≤51.82 ng/mL subgroups was not significant (*P*=0.04, *P*=0.24, *P*=0.97, *P*=0.12, and *P*=0.27; A, B).

DPD activities between C~SN-38\ 49h~\>14.34 and ≤14.34 ng/mL subgroups
----------------------------------------------------------------------

Comparison of the DPD activities between the C~SN-38\ 49h~\>14.34 and ≤14.34 ng/mL subgroups showed that the enzyme activities of the former were clearly lower than those of the latter (3.24±1.02 vs 4.93±2.08, *F*=11.20, *P*=0.001; [Figure 2C](#f2-cmar-10-6217){ref-type="fig"}).

mPFS of DPD activities between \>4.13 and ≤4.13 subsets in C~SN-38\ 49h~\>14.34 and ≤14.34 ng/mL subgroups
----------------------------------------------------------------------------------------------------------

By setting DPD activities as dependent variables and clinical parameters such as short-term response, PFS, OS, and ADRs as independent variables, stepwise regression indicated that DPD activities were related to the bone marrow hypocellularity and increased alanine aminotransferase (*t*=--3.03 and *t*=--2.75, *P*=0.003 and *P*=0.007; [Table 2](#t2-cmar-10-6217){ref-type="table"}), and the mPFS of DPD activities of the \>4.13 and≤4.13 subsets divided based on the adjusted predictive values and stand errors did not greatly differ in the C~SN-38\ 49h~\>14.34 ng/mL subgroup (6.83±0.33 vs 7.27±0.53 months, χ^2^=0.07, *P*=0.85; [Figure 3](#f3-cmar-10-6217){ref-type="fig"}).

Discussion
==========

Dosage individualization of chemotherapeutic drugs is an important factor in personalized cancer treatment, and it has been widely acknowledged in mCRC that CPT-11-associated life-threatening ADRs can be avoided by screening out the UGT1A1 homozygous genotype before administration of CPT-11-based chemotherapy;[@b14-cmar-10-6217],[@b15-cmar-10-6217] however, meta-analysis and studies did not confirm the relationship between the UGT1A1^\*^6 and ^\*^28 genotypes and clinical outcomes,[@b3-cmar-10-6217],[@b16-cmar-10-6217]--[@b19-cmar-10-6217] but individual dose adjustment is difficult based only on the UGT1A1 genotype. Moreover, most Asian populations have wild-type UGT1A1 or a heterozygous genotype, and the risks of CPT-11-associated serious ADRs are much lower than those for the homozygous genotype according to some meta-analyses, as SN-38 glucuronidation of the former two has been completely saturated.[@b20-cmar-10-6217] Therefore, the main purpose of personalized CPT-11 administration is to improve the therapeutic effect by dosage adjustment based on SN-38 pharmacokinetics. The MTD restricts dose escalation because of the factors such as the dose increase extent, escalation intervals, and patients' compliance, leading to different subclinical doses administered to patients and distress in judging the outcomes of CPT-11. Accordingly, it is necessary to take SN-38 pharmacokinetics into account when the correlation between different genotypes and outcomes are evaluated, particularly for the heterozygous genotype, which accounts for a large proportion of patients and shows variable UGT1A1 activities.[@b5-cmar-10-6217],[@b21-cmar-10-6217]

Previous studies of pharmacokinetics showed that the plasma CPT-11 levels reached a peak at 1.5 hours and decreased to minimum levels at 25.5 hours after intravenous CPT-11 infusion,[@b22-cmar-10-6217] and thus, the plasma SN-38 levels at 1.5 and 49 hours after CPT-11 infusion were evaluated to reflect the metabolism of CPT-11 in this study to examine CPT-11 dose individualization over a relatively short period. It is difficult to determine MTD by computing the AUC[@b8-cmar-10-6217],[@b23-cmar-10-6217] because of factors such as repeated blood sampling, high cost of the examination, long submission cycle, difficult promotion, and poor compliance of patients. Our results showed that the C~SN-38\ 1.5h~ and C~SN-38\ 49h~ of the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes were close to that of the ^\*^1/^\*^1-^\*^1/^\*^1 genotype, but significantly lower than that of the ^\*^1/^\*^28-^\*^1/^\*^6 genotype (as shown in [Figure 2](#f2-cmar-10-6217){ref-type="fig"}), indicating that the UGT1A1 activities of the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes were similar to that of the ^\*^1/^\*^1-^\*^1/^\*^1 genotype. Thus, we selected the ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes for retrospective analysis because of the relatively low risk of ADRs for dose personalized adjustment of CPT-11. [Table 1](#t1-cmar-10-6217){ref-type="table"} shows that the clinical characteristics of the two genotypes were comparable in combined analysis, and stepwise regression analysis revealed that C~SN-38\ 1.5h~ was relevant to PFS and C~SN-38\ 49h~ was associated with ADRs such as bone marrow hypocellularity. Further analysis indicated that the mPFS of the C~SN-38\ 1.5h~\>51.82 ng/mL subgroup was significantly longer than that of the ≤51.82 ng/mL subgroup, whereas no difference of mPFS was observed between the C~SN-38\ 49h~\>14.34 and≤14.34 ng/mL subgroups, suggesting that the efficacy can be improved by increasing the CPT-11 dose while monitoring C~SN-38\ 1.5h~ in the C~SN-38\ 1.5h~≤51.82 ng/mL subgroup.

For ADRs, we found no significant difference between the C~SN-38\ 1.5h~\>51.82 and≤51.82 ng/mL subgroups; however, the ADRS incidence in the C~SN-38\ 49h~\>14.34 ng/mL subgroup was significantly higher than that in the ≤14.34 ng/mL subgroup. Although a previous study indicated that 5-FU did not change the metabolic process of CPT-11 within a regular dose range,[@b24-cmar-10-6217] the determination of CPT-11-associated ADRs can be affected because similar 5-FU-correlated ADRs are caused by decreased or inhibited DPD activities. To evaluate the high incidence of ADRs in the C~SN-38\ 49h~\>14.34 ng/mL subgroup, stepwise regression was conducted, which showed that when DPD activities were correlated with bone marrow hypocellularity and increased alanine aminotransferase, the DPD activities of C~SN-38\ 49h~\>14.34 ng/mL subset were remarkably lower than that of the ≤14.34 ng/mL subset; however, there was no significant difference in mPFS between the DPD activities \>4.13 subset and ≤4.13 subset ([Figure 2C](#f2-cmar-10-6217){ref-type="fig"}), indicating that 5-FU-associated ADRs due to decreased activities of DPD were misclassified as CPT-11-related ADRs caused by reduced UGT1A1 activities. This leads to mistaken down-regulation of the CPT-11 dose, and thus, the activity or SNPs of DPD must be determined before adjusting the 5-FU dosage before CPT-11-based chemotherapy. In addition, reducing the doses of 5-FU did not affect the outcomes.

Subsequent dose individualization of CPT-11 and its effect on outcomes require further analysis via plasma 5-FU levels monitoring, improving the stability and repeatability of the method to detect the plasma SN-38 levels, and conducting prospective randomized controlled studies with larger samples. In addition, other biomarkers such as members of the ATP-Binding Cassette Subfamily C (ABCC),[@b25-cmar-10-6217]--[@b27-cmar-10-6217] organic anion-transporting polypeptide 1B1,[@b28-cmar-10-6217],[@b29-cmar-10-6217] and other factors including obesity[@b30-cmar-10-6217] and human organ function[@b31-cmar-10-6217],[@b32-cmar-10-6217] require further analysis to identify better biomarkers or combinations of biomarkers for predicting the efficacy and/or ADRs of CPT-11-based chemotherapy.

Conclusion
==========

According to our analyses, a dose increase of CPT-11 based on C~SN-38\ 1.5h~ may improve the efficacy in patients with lower C~SN-38\ 1.5h~ levels. For cases with relatively low DPD activity, advisable primary and subsequent dose adjustment of 5-FU based on the plasma 5-FU levels may be a practical strategy for reducing the incidence of 5-FU-associated ADRs for individualized administration of CPT-11 to those with the UGT1A1^\*^6 or ^\*^28 heterozygous type.
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![Sequencing results of UGT1A1^\*^28 and ^\*^6 SNPs and distributive characteristics of different SNP combinations for mCRC patients.\
**Notes:** DNA sequencing for wild-type UGT1A1^\*^28 (**A**) and UGT1A1^\*^6 (**D**), heterozygous type UGT1A1^\*^28 (**B**) and UGT1A1^\*^6 (**E**), and homozygous type UGT1A1^\*^28 (**C**) and UGT1A1^\*^6 (**E**) by FinchTV^®^ software. (**G**) The pie chart gives the proportion of the different combinations of wild-type (^\*^1/^\*^1-^\*^1/^\*^1 genotype: 244 cases, which accounted for 48.90%), heterozygous type (^\*^1/^\*^28-^\*^1/^\*^1, ^\*^1/^\*^1-^\*^1/^\*^6, and ^\*^1/^\*^28-^\*^1/^\*^6 genotype: 234 cases, which accounted for 46.89%), and heterozygous type (^\*^28/^\*^28-^\*^1/^\*^1, ^\*^1/^\*^1-^\*^6/^\*^6, ^\*^1/^\*^28-^\*^6/^\*^6, and ^\*^28/^\*^28-^\*^1/^\*^6 genotype: 21 cases, which accounted for only 4.21%).\
**Abbreviations:** mCRC, metastatic colorectal cancer; SNP, single-nucleotide polymorphism; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.](cmar-10-6217Fig1){#f1-cmar-10-6217}

![C~SN-38\ 1.5h~ and C~SN-38\ 49h~ between UGT1A1^\*^6 and ^\*^28 wild-type and UGT1A1^\*^6 and ^\*^28 heterozygous genotype as well as DPD activities between C~SN-38\ 49h~\>14.34 ng/mL and ≤14.34 ng/mL subgroups.\
**Notes:** The C~SN-38\ 1.5h~ of ^\*^1/^\*^1-^\*^1/^\*^1 genotype was 60.84±11.13 ng/mL, having no significant difference with those of ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotype (61.74±11.49 and 63.10±10.29 ng/mL, *P*=0.57 and 0.13, respectively), but with statistical difference being found in that of ^\*^1/^\*^28-^\*^1/^\*^6 genotype (75.10±23.16 ng/mL, *P*\<0.001, seen in **A**). Likewise in C~SN-38\ 49h~, the C~SN-38\ 49h~ of ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotype were 11.49±5.06 and 10.29±3.70 ng/mL, respectively, which did not differ obviously from that of ^\*^1/^\*^1-^\*^1/^\*^1 genotype (11.13±4.95 ng/mL, *P*=0.52 and 0.13), while being significantly different from that of ^\*^1/^\*^28-^\*^1/^\*^6 genotype (23.16±6.95 ng/mL, *P*\<0.001, shown in **B**). In **C**, the DPD activity of C~SN-38\ 49h~\>14.34 ng/mL subgroup was 3.24±1.02, remarkably lower than that of C~SN-38\ 49h~≤14.34 ng/mL subgroup with obvious difference (4.93±2.08, *F*=11.20, *P*=0.001).\
**Abbreviations:** CPT-11, irinotecan; C~SN-38\ 1.5h~, plasma SN-38 level 1.5 hours after CPT-11 administration; C~SN-38\ 49h~, plasma SN-38 level 49 hours after CPT-11 administration; DPD, dihydropyrimidine dehydrogenase; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.](cmar-10-6217Fig2){#f2-cmar-10-6217}

![mPFSs of the corresponding C~SN-38\ 1.5h~ and C~SN-38\ 49h~ subgroups in ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotype and mPFS of DPD activities between \>4.13 and ≤4.13 subsets in C~SN-38\ 49h~ \>14.34 ng/mL and ≤14.34 ng/mL subgroups, respectively, accordingly.\
**Notes:** No statistical difference was observed about the mPFS among ^\*^1/^\*^28-^\*^1/^\*^1,^\*^1/^\*^1-^\*^1/^\*^6, and ^\*^1/^\*^28-^\*^1/^\*^6 genotypes (**A**) (6.73±0.13 months vs 6.73±0.18 months vs 6.80±0.32 months, χ^2^=1.11, *P*=0.57), but differences were displayed clearly between the mPFS of C~SN-38\ 1.5h~\>51.82 ng/mL and that of ≤51.82 ng/mL subgroup in ^\*^1/^\*^28-^\*^1/^\*^1 (**B**) and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes (**C**) (6.83±0.17 vs 4.87±0.13 months, *P*\<0.001; 6.93±0.34 vs 5.63±0.31 months, *P*\<0.001), which were divided by the adjusted predictive values and stand errors of C~SN-38\ 1.5h~, while the mPFS did not differ between C~SN-38\ 49h~\>14.34 ng/mL and ≤14.34 ng/mL subgroups grouped by the same way in ^\*^1/^\*^28-^\*^1/^\*^1 (**D**) and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes (**E**) (6.83±0.48 vs 6.63±0.13 months, *P*=0.80; 7.27±0.35 vs 6.70±0.21 months, *P*=0.59). The mPFS of DPD activities \>4.13 and ≤4.13 subset divided based on the adjusted predictive values and stand errors did not differ obviously in C~SN-38\ 49h~\>14.34 ng/mL and ≤14.34 ng/mL subgroups of ^\*^1/^\*^28-^\*^1/^\*^1 (**F**) and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes (**G**) (6.83±0.33 vs 7.27±0.53 months, χ^2^=0.04, *P*=0.85; 6.60±0.12 vs 6.73±0.22 months, χ^2^=0.07, *P*=0.79).\
**Abbreviations:** CPT-11, irinotecan; C~SN-38\ 1.5h~, plasma SN-38 level 1.5 hours after CPT-11 administration; C~SN-38\ 49h~, plasma SN-38 level 49 hours after CPT-11 administration; DPD, dihydropyrimidine dehydrogenase; mPFS, median PFS; PFS, progression-free survival.](cmar-10-6217Fig3){#f3-cmar-10-6217}

![ADRs between corresponding C~SN-38\ 1.5h~ and C~SN-38\ 49h~ subgroups in ^\*^1/^\*^28-^\*^1/^\*^1 and ^\*^1/^\*^1-^\*^1/^\*^6 genotypes.\
**Notes:** It was not significantly distinguished between C~SN-38\ 1.5h~\>51.82 ng/mL and ≤51.82 ng/mL subgroups (**A**) (*F*=6.58, *P*=0.04; *F*=2.86, *P*=0.24; *F*=0.002, *P*=0.97; *F*=2.39, *P*=0.12; and *F*=1.20, *P*=0.27). However, the incidence of bone marrow hypocellularity, diarrhea, increased alanine aminotransferase, nausea, and oral mucositis in C~SN-38\ 49h~\>14.34 ng/mL subgroup was higher than that in ≤14.34 ng/mL subgroup with statistical difference (**B**) (*F*=26.09, *P*\<0.001; *F*=57.92, *P*\<0.001; *F*=11.63, *P*\<0.001; *F*=38.04, *P*\<0.001; and *F*=49.20, *P*\<0.01). ADRs were graded by CTCAE v 4.03.\
**Abbreviations:** ADR, adverse reaction; CPT-11, irinotecan; CTCAE, Common Terminology Criteria for Adverse Events; C~SN-38\ 1.5h~, plasma SN-38 level 1.5 hours after CPT-11 administration; C~SN-38\ 49h~, plasma SN-38 level 49 hours after CPT-11 administration.](cmar-10-6217Fig4){#f4-cmar-10-6217}

###### 

Clinical characteristics between UGT1A1\*28 and \*6 heterozygous genotypes

  Clinical characteristics     \*1/\*28-\*1/\*1 genotype (n=98)   \*1/\*1-\*1/\*6 genotype (n=116)   *F*    *P*
  ---------------------------- ---------------------------------- ---------------------------------- ------ ------
  ECOG performance score                                                                             0.10   0.75
   0                           52                                 59                                        
   1                           46                                 57                                        
  Gender                                                                                             2.39   0.12
   Male                        61                                 60                                        
   Female                      37                                 56                                        
  Median age (years)           55.55                              54.90                              0.03   0.87
  Primary tumor site                                                                                 1.76   0.19
   Colon                       46                                 65                                        
   Rectum                      52                                 51                                        
  TMN staging                                                                                        0.01   0.91
   IIIb                        8                                  9                                         
   IV                          90                                 107                                       
  Metastatic organs                                                                                  0.95   0.62
   1                           71                                 87                                        
   2                           22                                 26                                        
   3                           5                                  3                                         
  Chemotherapy cycles          8.26±2.74                          9.78±2.32                          5.09   0.03
  CPT-11 initial dosage (mg)   293.60±30.28                       292.33±28.29                       0.82   0.37
  DPD activity (UH2/U)         4.59±2.17                          4.83±1.86                          0.46   0.50

**Abbreviations:** CPT-11, irinotecan; DPD, dihydropyrimidine dehydrogenase; ECOG, East Cooperative Oncology Group; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.

###### 

Stepwise regression of C~SN-38\ 1.5h~, C~SN-38\ 49h~, and DPD activity for \*1/\*28-\*1/\*1 and \*1/\*1-\*1/\*6 genotypes

                                       Associated clinical parameters   95% CI   *t*     *P*-value   Mean of adjusted predicted value   Standard error of predicted value   
  ------------------------------------ -------------------------------- -------- ------- ----------- ---------------------------------- ----------------------------------- -------
  C~SN-38\ 1.5h~ (ng/mL)               Constant                         20.21    29.36                                                  62.51                               10.69
  PFS                                  5.77                             7.30     16.81   \<0.001                                                                            
  C~SN-38\ 49h~ (ng/mL)                Constant                         6.34     7.66    20.92                                          10.84                               3.50
  Bone marrow hypocellularity          2.14                             3.37     8.82    \<0.001                                                                            
  Increased alanine aminotransferase   1.19                             2.73     5.02    \<0.001                                                                            
  Diarrhea                             1.37                             3.24     4.84    \<0.001                                                                            
  DPD activity                         Constant                         4.89     5.75    24.20                                          4.66                                0.53
  Bone marrow hypocellularity          −1.23                            −0.20    −2.75   0.007                                                                              
  Increased alanine aminotransferase   −0.81                            −0.17    −3.03   0.003                                                                              

**Abbreviations:** CPT-11, irinotecan; C~SN-38\ 1.5h~, plasma SN-38 level 1.5 hours after CPT-11 administration; C~SN-38\ 49h~, plasma SN-38 level 49 hours after CPT-11 administration; DPD, dihydropyrimidine dehydrogenase; PFS, progression-free survival.
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